Total Health
Total Health is the largest provider of free cancer care resources for people who are treating or living with cancer. Our programs arm cancer care teams with the latest research and strategies to improve patient outcomes.
For more info visit our website at Total Health.
Jacksonville
2020 ASCO Virtual Direct™ Highlights
FDA Approved Pralsetinib (BLU-667) in RET+ mNSCLC: ARROW Trial Overview
FEATURING
Michael Shafique
- 27 views
- April 13, 2021
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Update on HRAS-Mutant HNSCC: Does Tipifarnib Show Treatment Potential?
FEATURING
Anterpreet Neki
- 5 views
- January 5, 2021
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Update on ctDNA: Can We Use ctDNA as a Marker of MRD Following Definitive Treatment in Localized NSCLC? Is the Absence of Detectable BRAFV600 ctDNA at Baseline Associated With Improved PFS and OS in Pts Receiving Dabrafenib and Trametinib?
FEATURING
Martin Dietrich
- 117 views
- November 11, 2020
2020 ASCO Virtual Direct™ Highlights
ASCO 2020 Highlights on PC: 18F-DCFPyL-PET/CT and Clinical Impact on BCRPC - Results from the CONDOR Study
FEATURING
Bruno Bastos
- 56 views
- September 29, 2020
2020 ASCO Virtual Direct™ Highlights
ASCO 2020 Updates on Advanced PC: Relugolix vs. Leuprolide Acetate in Testosterone Suppression - Is It Practice Changing?
FEATURING
Bruno Bastos
- 122 views
- September 29, 2020
- 1
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Updates on IDH1-Mutated AML: Do Ivosidenib & Venetoclax Work Better Alone or in Combination With Azacitidine?
FEATURING
Terrence Bradley
- 143 views
- September 29, 2020
- 1
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Highlights on R/R AML: Is AMG 330 Safe and Tolerable? How Should We Manage CRS?
FEATURING
Terrence Bradley
- 45 views
- September 29, 2020
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Updates on MDS/AML: How Does Magrolimab Work With AZA? What Is the Effect on the TP53 Mutation?
FEATURING
Terrence Bradley
- 91 views
- September 29, 2020
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Updates on High-Risk MIBC: Can We Improve DFS/OS With Adjuvant Atezo?
FEATURING
Winston Tan
- 41 views
- September 28, 2020
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Updates on Advanced UC: How Does Maintenance Avelumab + BSC After 1L Chemo Affect OS?
FEATURING
Winston Tan
- 36 views
- September 28, 2020
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Updates on IO in ES-SCLC: Should You Recommend 1L IO+EP Combination Instead of EP Alone?
FEATURING
John Vu
- 70 views
- September 28, 2020
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Highlights on mNSCLC: Will the Efficacy of T-DXd in HER2+ Disease Add HER2 Mutation to the List of Essential NSCLC Biomarkers? OS With Bevacizumab + Erlotinib in EGFR+ NSCLC - Does It Change the Role of Osimertinib in 1L Therapy?
FEATURING
Michael Shafique
- 80 views
- September 25, 2020
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Highlights on Stage 3 Rectal Cancer: Preoperative Short-Course RT, Followed by Chemo and TME vs. Conventional CRT - Which Option Leads to a Lower Rate of DrTF? Can Patients With a cCR to Neoadjuvant Skip Surgery?
FEATURING
Jason Starr
- 816 views
- September 16, 2020
- 5
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Melanoma Updates: Optimal Dosing Schedule of Neoadjuvant Ipi + Nivo, Adjuvant Pembro in Resected High-Risk Stage III, Adjuvant Dabrafenib + Trametinib in BRAF V600E Stage III, Pembro vs. Ipi in Advanced Melanoma
FEATURING
Ari VanderWalde
- 83 views
- August 25, 2020
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Update on R/R Hodgkin Lymphoma: Can We Consider Pembrolizumab a New SoC?
FEATURING
William Hammond
- 146 views
- August 25, 2020
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Update on Lymphomas: Is Axi-Cel Effective in R/R Indolent Lymphoma?
FEATURING
William Hammond
- 136 views
- August 25, 2020
- 1
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Update on CLL: Does Venetoclax + da-EPOCH-R Show Promise for Richter’s Syndrome?
FEATURING
William Hammond
- 116 views
- August 25, 2020
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Update on OS Data for Recent FDA Approved Olaparib
FEATURING
Gerardo Colon-Otero
- 86 views
- July 29, 2020
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Update on De-Escalation in Early Stage HER2+ BC: Should All Patients Receive Neoadjuvant Chemotherapy Just Because They Have HER2+ Disease? Can 6 vs. 12 Months of Anti-HER2 Therapy Be Equally Effective?
FEATURING
Alvaro Moreno-Aspitia
- 242 views
- August 26, 2020
